Simplex Trading’s PharmaCyte Biotech PMCB Stock Holding History

Simplex Trading’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,940	Closed	-$15K	–	10093
2026 Q1	$13.3K	Sell	19,940 -5,894	-23%	-$4.51K	﹤0.01%	7100
2025 Q4	$18.7K	Buy	25,834 +24,734	+2,249%	+$22.3K	﹤0.01%	6537
2025 Q3	$1K	Buy	+1,100	New	+$1.1K	﹤0.01%	8858
2023 Q4	–	Sell	-199	Closed	–	–	9579
2023 Q3	$0	Sell	199 -46,950	-100%	-$120K	﹤0.01%	9564
2023 Q2	$134K	Sell	47,149 -86,051	-65%	-$258K	﹤0.01%	4743
2023 Q1	$387K	Buy	133,200 +69,592	+109%	+$205K	﹤0.01%	3545
2022 Q4	$186K	Sell	63,608 -1,812	-3%	-$5.19K	﹤0.01%	4313
2022 Q3	$157K	Buy	65,420 +10,493	+19%	+$26.5K	﹤0.01%	4939
2022 Q2	$123K	Buy	+54,927	New	+$120K	﹤0.01%	5279

Other funds holding PMCB

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Simplex Trading's PMCB Position: Q2 2026 in Review

Simplex Trading sold out of PharmaCyte Biotech (PMCB) in Q2 2026, closing a stake of 19,940 shares — an estimated $15K sold.

Simplex Trading first reported a position in PMCB in Q2 2022 and held it in 9 quarters. The position peaked at $387K in Q1 2023. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

Simplex Trading reported no remaining PharmaCyte Biotech position as of Q2 2026 after selling out during the quarter.
Simplex Trading sold 19,940 PharmaCyte Biotech shares in Q2 2026, an estimated $15K.
Simplex Trading first reported a position in PharmaCyte Biotech in Q2 2022 and held it in 9 quarters.
Simplex Trading's PharmaCyte Biotech position peaked at $387K in Q1 2023.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.